# A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)

> **NCT03398005** · PHASE3 · COMPLETED · sponsor: **Grace Therapeutics Inc.** · enrollment: 256 (actual)

## Conditions studied

- Hypertriglyceridemia

## Interventions

- **DRUG:** CaPre
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03398005
- **Lead sponsor:** Grace Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-23
- **Primary completion:** 2019-07-21
- **Final completion:** 2019-11-20
- **Target enrollment:** 256 (ACTUAL)
- **Last updated:** 2020-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03398005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03398005, "A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03398005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*